TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: World Health Organization Disability Assessment Schedule II (WHODAS-II) for Patients With Symptomatic Lumbar Spinal Stenosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients seen for symptomatic lumbar spinal stenosis~* With signs of neurogenous claudication~* MRI or CAT scan concordant with observed signs~* Able to read and write~* Have signed the informed consent form~Exclusion Criteria:~* Central nervous system pathology (with or without treatment)~* Diagnosis of rheumatic inflammatory disease or fibromyalgia~* Red flags for underlying systemic disease~* Criteria for diagnosis of disc herniation~* Symptoms suggesting saddle anesthesia, cauda equina, loss of sphincter tone or paraparesis~* Motor deficit that progresses or does not improve in 6 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): Measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed estrogen and/or progesterone receptor-positive breast cancer metastatic breast cancer~* Clinically determined evaluable disease~* Post-menopausal woman~* Previous clinical benefit from prior anti-estrogen therapies and subsequent failure of at least 2 prior endocrine therapies.~* May have had chemotherapy for adjuvant \&/or metastatic disease.~* May have had radiation therapy but not to the only site of disease.~* Ecog performance status \</= 2.~* Life expectancy of \> 6 months~Exclusion Criteria:~* Chemotherapy or radiotherapy within 1 week of beginning treatment in the clinical trial~* Brain metastasis~* Prior history of or active thrombophlebitis, deep venous thrombosis or pulmonary embolus~* Current vaginal bleeding~* Hypercalcemia or hypocalcemia~* History of or active hepatic adenoma~* No other malignancies within the past 5 years with the exception of curatively treated basal cell or squamous cell carcinoma of the skin or carcinoma in-situ of the cervix

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Estrace & Anastrozole (Type: EXPERIMENTAL): Estrace 10 mg three times a day for 3 months. After 3 months of estrace, the estrace will be stopped and anastrazole 1 mg daily will be administered

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Early Versus Late Upper Extremity Mobilization After Autograft

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years and older at the time of surgery.~2. Injury: Acute (within 72h of injury) thermal flame or scald burn.~3. Surgery: Skin split-thickness meshed autograft (STSG) applied directly on the wound bed.~4. Location: Upper extremity burn - distal to the axilla and proximal to the wrist.~Exclusion Criteria:~1. Injury: Electrical and chemical burn.~2. Location: Autograft exclusively to the wrist, hand, axilla or non-upper extremity.~3. Patients on vasopressors the day of the operation.~4. Pre-existing comorbidities causing upper extremity mobility restrictions.~5. Patient unable to comply with mobilization protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Early mobilization (Type: EXPERIMENTAL): None
- Late mobilization (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessing Performance on Speech Tasks Via Crowdsourced Participants

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* First language must be English~* Residing in the USA~* Willing to participate in a study investigating speech and dementia~* Able to provide informed consent~* Access to personal computing device that is capable of audio and video recording, and able to connect to the internet~Since key research questions are focused primarily on older-age speech and cognition, initial recruitment will be focused on older adult age brackets, which may be extended to younger adulthood if the desired sample sizes are not attained.~Exclusion Criteria:~* No formal exclusion criteria will apply at the point of recruitment and testing. however, participants with a reported history of neurological conditions or head injury, and current depression will be excluded from normative data development.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- AMYWEB-Normative (Type: None): This cohort assessed over six recruitment and test phases, will be sampled to be as closely representative of the demographic population as possible.
- AMYWEB-Diversity (Type: None): This cohort assessed over two recruitment and test phases will oversample participants from minority and mixed ethnic and racial backgrounds as well as participants from lower educational backgrounds.
- AMYWEB-MCI (Type: None): This cohort assessed and recruited over one test phase, will include participants with a reported diagnosis of mild cognitive impairment or dementia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Disease Characteristics:~* Patients with a documented histologic or cytologic diagnosis of B-cell NHL.~* Patients who have failed at least one regimen of chemotherapy and are not eligible for any alternate therapies of higher therapeutic priority.~* Patients with at least one measurable tumor site \> 1.5 cm in at least one dimension.~Prior/Concurrent Therapy:~* Chemotherapy: Patients must have failed standard therapy or are not eligible for any alternate therapies of higher therapeutic priority.~* Biologic Therapy: Patients who have received human or humanized monoclonal antibodies will be eligible provided pre-study evaluations demonstrate no significant reactivity with hLL2 IgG (i.e., HAHA).~* Radiotherapy: No prior radiation therapy to \>25% of the bone marrow. No prior radiation to maximal tolerable levels for any critical organ (e.g., 2,000 cGy for the lungs and kidneys). Patients who have had whole pelvic irradiation are not eligible.~Patient Characteristics/Inclusion Criteria:~* Age Range: Male or Female at least 18 years of age~* Performance Status: Patients with a Karnofsky performance status \> 60% (or equivalent, ECOG 0-2) and expected survival of at least 12 weeks.~* Hematopoietic: Hemoglobin \> 10 g/dL; ANC \> 1.5x10\^9/L; Platelets \> 100x10\^9/L;~* Hepatic: Serum bilirubin \< 2.0 mg/dL; AST and ALT \< 2 x ULN w/o liver metastases or \<5 x ULN w/liver metastases~* Renal: Creatinine \< 2.0 mg/dL~* Cardiovascular: Patients with LVEF \>/= 50% by MUGA or 2D-ECHO.~* Pulmonary: Patients with DFCO and FEV1 \>/= 60% by required Pulmonary Function Tests.~* Other: Patients agreeing to use a medically effective method of contraception while enrolled in the study. A pregnancy test will be performed on each premenopausal female of childbearing potential immediately prior to entry into the study. Patients able to understand and give written informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Electronic Fetal Monitoring With and Without Pattern Interpretation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Women who have a singleton pregnancy.~* Women admitted for labor to Ayder Referral Hospital in Mekelle, Ethiopia.~* Pregnant women aged 18 years or older.~* Receiving EFM for intrapartum management.~* Patients assigned to receive EFM will be designated by the current protocol regarding high risk vs. low risk patients at Ayder Referral Hospital as per discretion of the supervising provider in Labor and Delivery.~Exclusion Criteria:~* Women who are carrying multiple gestation.~* Pregnant women under 18 years of age.~* Low risk women who are undergoing IA.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- Without Pattern Interpretation (Type: None): All women who are admitted for labor at Ayder Referral Hospital in Mekelle, Ethiopia will be asked to participate and a physician will obtain consent. If an indication arises and they are designated to receive EFM per previously established standard practice at Ayder Hospital, then their patient information will be collected. Patients who require EFM will be asked to provide basic health and demographic information, along with collection of information on labor and delivery course, post-partum outcome, and neonatal outcomes. The investigators estimate enrollment of up to 1800 patients which will result in at least 300 patients who will require EFM.
- With Pattern Interpretation (Type: None): All women who are admitted for labor at Ayder Referral Hospital in Mekelle, Ethiopia will be asked to participate and a physician will obtain consent. If an indication arises and they are designated to receive EFM per previously established standard practice at Ayder Hospital, then their patient information will be collected.~Their labor will be managed as in Phase 1 except that EFM will be interpreted and managed as per ACOG/FIGO guidelines using paper on which fetal heart tracings will be recorded. All other aspects of their care will proceed as per standard at Ayder Referral Hospital.~Patients who require EFM will be asked to provide basic health and demographic information, along with collection of information on labor and delivery course, post-partum outcome, and neonatal outcomes. The investigators estimate enrollment of up to 1800 patients which will result in at least 300 patients who will require EFM.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and Female patients age 18 years or older~* COVID-19 confirmed positive test results~* High risk for complications including with Medium (5-6) or High (More than or equal to 7) NEWS score~* Hematology criteria: ANC \>500 cells/mcl, HGB \>9 g/dl, Platelet count \>75,000/mcl~* Metabolic criteria: Serum creatinine \<2.0 mg/dl or calculated creatinine clearance (using Cockcroft-Gault) \>30 ml/min, AST/ALT \<5x ULN AND Total Bilirubin WNL (for patients with Gilbert's disease, direct bilirubin \<ULN)~Exclusion Criteria:~* COVID-19 negative test result~* Inability to adhere to study protocol requirements~* Inability to provide informed consent~* Other acute or chronic medical or psychiatric condition that in the judgment of the investigator would make the participant inappropriate to take part in the study~* Pregnant and breastfeeding individuals~* QTc interval greater than 470 msecs at baseline~* History of hypersensitivity to atovaquone and/or azithromycin.~* History of known intolerance to atovaquone and/or azithromycin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Atovaquone/Azithromycin (Type: EXPERIMENTAL): Atovaquone 750 mg PO Q12H for up to 10 days Azithromycin 500 mg PO Day 1 followed by 250 mg PO daily for up to 10 days (Days 2-10)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Image Guided Reirradiation of High-grade Glioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* recurrent high-grade glioma~* previous focal radiotherapy for high-grade glioma~* no standard treatment options available/indicated~* ECOG (Eastern Cooperative Oncology Group) performance status 0 or 1 or 2~* life expectancy \> 3 months~* hemoglobin value \> 6 mmol/l (transfusion permitted)~* able to understand oral and written Danish~Exclusion Criteria:~* disseminated recurrent disease~* infection or wound dehiscence or other pathological condition in meninges/skull/scalp~* symptoms of elevated intracranial pressure~* very early recurrence following primary radiotherapy (\< or equal to 3 months)~* contraindications to magnetic resonance imaging (MRI) or positron emission tomography (PET)~* other previous radiotherapy to the brain than primary course of irradiation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- External beam radiotherapy (Type: EXPERIMENTAL): Hypofractionated external beam radiation delivered in 4 different sequential dose/fractionation groups.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy And Safety Of The Uro-Ease® Urinary Catheter During Clean Intermittent Catheterization

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CROSSOVER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male patients~* Urinary retention defined as \>150cc retained in bladder on post void residual~Exclusion Criteria:~* Female patients~* Known urethral stricture~* Active symptomatic Urinary Tract Infection~* History of pelvic fracture or urethral disruption~* History of previous urethroplasty(urethral reconstructive surgery)~* Known Latex allergy~* Unable to physically perform CIC~* Unable to provide follow up~* Unable to give consent~* Currently taking chronic narcotic pain medication

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Uro-Ease Spirus Catheter (Type: None): 10 patients randomized to the Uro-Ease Catheter group for 1 week. In clinic, patients will be instructed in the use of the Uro-Ease Catheter. A QOL form will be filled out measuring comfort and ease of use and subsequently after each catheterization. Patients will also record time per catheterization and bladder drainage. Patients will return to Clinic in 1 week to check progress and will then change to a standard, non-helical urinary catheter. Patients will be followed up to 1 month.
- Standard Urinary Catheter (Type: None): 10 patients randomized to a Standard Urinary Catheter group for 1 week. In clinic, patients will be instructed in the use of the catheter. A QOL form will be filled out measuring comfort and ease of use and subsequently after each catheterization. Patients will also record time per catheterization and bladder drainage. Patients will return to Clinic in 1 week to check progress and will then change to the UroEase Spirus Catheter. All patients will be followed up to 1 month.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient suffering from a major depressive episode (unipolar only) AND alcohol dependence or abuse; Score of greater than 16 on the HDRS~* Age range 18-65 years~* History of a past suicide attempt, defined as self destructive behavior with at least some intent to die; patients with suicidal plan or intent will only be enrolled as inpatients if staff agrees it is reasonable.~* Able to tolerate cross taper to study medications~Exclusion Criteria:~* Other major psychiatric disorders such as Bipolar Disorder; schizophrenia or schizoaffective disorder, past or current psychotic symptoms; eating disorder; substance abuse or dependence (other than alcohol, caffeine or nicotine); persons already taking SSRIs or bupropion for other indications such as anxiety disorders.~* Primary disorder is an anxiety disorder such as Panic disorder/GAD/OCD/Social anxiety disorder, with secondary depression.~* CIWA-AR rating \>10 or history of delirium tremens or seizures.~* Blood pressure \>150 systolic or \>90 diastolic~* Active or untreated medical problems~* Antipsychotic medication required~* History of becoming hypomanic or manic on antidepressants~* Contraindication to the use of fluoxetine or bupropion, or currently using Zyban~* Failure to respond to adequate trials of 3 SSRIs or fluoxetine or bupropion in the last 2 years (failure to respond to therapeutic trial defined as: at least 2/3 maximal PDR dose for at least 6 weeks)~* Lack of capacity to consent~* Pregnancy, lactation, or plans to conceive during the course of study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): fluoxetine -- 6 months of antidepressant pharmacotherapy as well as psychotherapy focused on alcohol relapse prevention; patients will also be encouraged to attend daily Alcoholics Anonymous meetings
- 2 (Type: ACTIVE_COMPARATOR): bupropion -- 6 months of antidepressant pharmacotherapy as well as psychotherapy focused on alcohol relapse prevention; patients will also be encouraged to attend daily Alcoholics Anonymous meetings

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Vaginal Stump Infection After Laparoscopic Hysterectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient \> = 18 years old~2. Indication for total laparoscopic or robot-assisted hysterectomy~3. Benign uterine disease~4. Signed informed consent for study participation~Exclusion Criteria:~1. Patient with malignant gynecological diseases~2. Combination with other abdominal / vaginal interventions, except:~   * Adhesiolysis~  * Endometriosis removal (without rectovaginal endometriosis)~  * Conization~  * Hysteroscopy / curettage~3. Immunosuppressive therapy with cytostatics, glucocorticoids, HIV~4. Bleeding tendency / haemophilia~5. Acute infection

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (test surgical technique) (Type: EXPERIMENTAL): Colpotomy closure technique: 3 Z-suture with PDS 0 and 1 continuous suture with V-Loc 2-0
- Arm B (control surgical technique) (Type: ACTIVE_COMPARATOR): Colpotomy closure technique: 3 Z-suture with PDS 0

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hydroxychloroquine in Outpatient Adults With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria :~* Participants with diagnosis of COVID-19 via an approved or authorized molecular test~* Presence of symptoms compatible with COVID-19 at the time of screening~* Time between onset of symptoms and first dose of hydroxychloroquine or placebo is 96 hours or less~* Female participants must use an acceptable birth control method, as specified by each site and country~Exclusion criteria:~* COVID-19 disease requiring the use of supplemental oxygen~* Electrocardiogram (ECG) tracing with QTc interval \> 450 ms for men, \> 470 ms for women (Fridericia algorithm recommended)~* Bradycardia (\< 50 beats/min)~* History of cardiac disease (eg. congestive heart failure, myocardial infarction)~* History of Glucose-6-phosphate dehydrogenase (G6PD) deficiency~* Women who are pregnant or breastfeeding~* Concurrent antimicrobial therapy~* Known hypersensitivity to hydroxychloroquine or other 4-aminoquinoline compounds~* Hydroxychloroquine use within 2 months before enrollment~* History of severe skin reactions such as Sevens-Johnson syndrome and toxic epidermal necrolysis~* History of retinopathy~* History of arrythmia, concurrent use of anti-arrhythmic drugs, or family history of sudden cardiac death~* History of severe renal disease (treatment with dialysis or phosphate binders) or hepatic impairment~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Hydroxychloroquine (Type: EXPERIMENTAL): Hydroxychloroquine, loading dose on day 1 followed by a daily maintenance dose during 9 days
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues